2 weeks Ago By ABMN Staff
Legal & General Group Plc lessened its stake in Vir Biotechnology, Inc. ( NASDAQ:VIR – Free Report ) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The institutional investor owned 231,983 shares of the company’s stock after selling 26,953 shares during the quarter. Legal & General Group Plc owned about 0.17% of Vir Biotechnology worth $1,703,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. State of Alaska Department of Revenue raised its position in Vir Biotechnology by 33.0% during the fourth quarter.
State of Alaska Department of Revenue now owns 202,441 shares of the company’s stock valued at $1,485,000 after purchasing an additional 50,199 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Vir Biotechnology by 0.5% during the 4th quarter.
Rhumbline Advisers now owns 236,681 shares of the company’s stock worth $1,737,000 after buying an additional 1,288 shares in the last quarter. abrdn plc bought a new stake in shares of Vir Biotechnology during the 4th quarter worth $2,666,000. SBI Securities Co.
Ltd. acquired a new stake in Vir Biotechnology in the fourth quarter valued at about $60,000. Finally, Victory Capital Management Inc.
grew its position in Vir Biotechnology by 9.2% in the fourth quarter. Victory Capital Management Inc.
now owns 88,776 shares of the company’s stock valued at $652,000 after acquiring an additional 7,507 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.
Analyst Upgrades and Downgrades A number of equities research analysts have recently weighed in on VIR shares. HC Wainwright restated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, February 28th.
Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $10.00 to $20.00 in a research report on Thursday, January 9th.
JPMorgan Chase & Co. upped their price target on shares of Vir Biotechnology from $10.00 to $14.
00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. The Goldman Sachs Group dropped their price target on Vir Biotechnology from $28.00 to $21.
00 and set a “buy” rating for the company in a research note on Thursday, April 17th. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Thursday, February 27th.
One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.57.
Vir Biotechnology Stock Down 2.7 % NASDAQ VIR opened at $6.12 on Friday.
The company has a market capitalization of $844.95 million, a price-to-earnings ratio of -1.56 and a beta of 1.
14. Vir Biotechnology, Inc. has a twelve month low of $4.
95 and a twelve month high of $14.45. The stock has a fifty day simple moving average of $6.
90 and a 200 day simple moving average of $8.05. Vir Biotechnology ( NASDAQ:VIR – Get Free Report ) last issued its quarterly earnings results on Wednesday, February 26th.
The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.
09. The company had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.
14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.
40%. Research analysts expect that Vir Biotechnology, Inc. will post -3.
92 earnings per share for the current fiscal year. Insiders Place Their Bets In other news, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.
95, for a total value of $474,286.40. Following the completion of the transaction, the chief executive officer now directly owns 769,505 shares of the company’s stock, valued at approximately $4,578,554.
75. This trade represents a 9.39 % decrease in their position.
The transaction was disclosed in a legal filing with the SEC, which is accessible through this link . Also, Director George A. Scangos sold 10,964 shares of the business’s stock in a transaction dated Tuesday, February 18th.
The shares were sold at an average price of $9.81, for a total value of $107,556.84.
Following the completion of the transaction, the director now directly owns 708,295 shares in the company, valued at $6,948,373.95. This represents a 1.
52 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last 90 days, insiders sold 99,611 shares of company stock worth $663,525.
15.60% of the stock is currently owned by insiders. About Vir Biotechnology ( Free Report ) Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). Featured Stories Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.
com's FREE daily email newsletter ..
